{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:46:52Z","timestamp":1793234812696,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100024092","name":"University of Iowa Health Care","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100024092","id-type":"DOI","asserted-by":"crossref"}]},{"name":"American Heart Foundation","award":["25POST1374595"],"award-info":[{"award-number":["25POST1374595"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK116888"],"award-info":[{"award-number":["DK116888"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH1RO1HL134738"],"award-info":[{"award-number":["NIH1RO1HL134738"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH1R01DK123043"],"award-info":[{"award-number":["NIH1R01DK123043"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK124326"],"award-info":[{"award-number":["DK124326"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"crossref","award":["7-21-JDF-033"],"award-info":[{"award-number":["7-21-JDF-033"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001024","name":"Roy J. Carver Charitable Trust","doi-asserted-by":"publisher","award":["25-5906"],"award-info":[{"award-number":["25-5906"]}],"id":[{"id":"10.13039\/100001024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15778-z","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T10:21:11Z","timestamp":1755944471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-3659","authenticated-orcid":false,"given":"Adeyinka","family":"Taiwo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alan","family":"Maschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayotunde","family":"Dokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William I.","family":"Sivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirath","family":"Chaurasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"15778_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.064","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2020.05.064 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"12","key":"15778_CR2","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","volume":"105","author":"M de Vries","year":"2020","unstructured":"de Vries, M., Westerink, J., Kaasjager, K. & de Valk, H. W. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105(12), 3842\u20133853. https:\/\/doi.org\/10.1210\/clinem\/dgaa575 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"15778_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A. & Gastaldelli, A. Lipid metabolism in MASLD and MASH: From mechanism to the clinic. JHEP Rep. 6(12), 101185. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101185 (2024).","journal-title":"JHEP Rep."},{"issue":"22","key":"15778_CR4","doi-asserted-by":"publisher","first-page":"12737","DOI":"10.1073\/pnas.96.22.12737","volume":"96","author":"M Foretz","year":"1999","unstructured":"Foretz, M., Guichard, C., Ferre, P. & Foufelle, F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. U S A 96(22), 12737\u201312742. https:\/\/doi.org\/10.1073\/pnas.96.22.12737 (1999).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"3","key":"15778_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41580-018-0085-z","volume":"20","author":"JA Olzmann","year":"2019","unstructured":"Olzmann, J. A. & Carvalho, P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell Biol. 20(3), 137\u2013155. https:\/\/doi.org\/10.1038\/s41580-018-0085-z (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"15778_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","volume":"62","author":"CJ Pirola","year":"2013","unstructured":"Pirola, C. J. et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 62(9), 1356\u20131363. https:\/\/doi.org\/10.1136\/gutjnl-2012-302962 (2013).","journal-title":"Gut"},{"issue":"8","key":"15778_CR7","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/nu15081992","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Applying lipidomics to non-alcoholic fatty liver disease: A clinical perspective. Nutrient 15(8), 1992. https:\/\/doi.org\/10.3390\/nu15081992 (2023).","journal-title":"Nutrient"},{"issue":"1","key":"15778_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00125-010-1938-y","volume":"54","author":"N Stefan","year":"2011","unstructured":"Stefan, N., Staiger, H. & Haring, H. U. Dissociation between fatty liver and insulin resistance: The role of adipose triacylglycerol lipase. Diabetologia 54(1), 7\u20139. https:\/\/doi.org\/10.1007\/s00125-010-1938-y (2011).","journal-title":"Diabetologia"},{"key":"15778_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jbior.2018.11.004","volume":"70","author":"M Nikolova-Karakashian","year":"2018","unstructured":"Nikolova-Karakashian, M. Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide. Adv. Biol. Regul. 70, 40\u201350. https:\/\/doi.org\/10.1016\/j.jbior.2018.11.004 (2018).","journal-title":"Adv. Biol. Regul."},{"issue":"2","key":"15778_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MOL.0b013e3283373b66","volume":"21","author":"SA Summers","year":"2010","unstructured":"Summers, S. A. Sphingolipids and insulin resistance: The five Ws. Curr. Opin. Lipidol. 21(2), 128\u2013135. https:\/\/doi.org\/10.1097\/MOL.0b013e3283373b66 (2010).","journal-title":"Curr. Opin. Lipidol."},{"issue":"8","key":"15778_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4254\/wjh.v12.i8.436","volume":"12","author":"S Kartsoli","year":"2020","unstructured":"Kartsoli, S., Kostara, C. E., Tsimihodimos, V., Bairaktari, E. T. & Christodoulou, D. K. Lipidomics in non-alcoholic fatty liver disease. World J. Hepatol. 12(8), 436\u2013450. https:\/\/doi.org\/10.4254\/wjh.v12.i8.436 (2020).","journal-title":"World J. Hepatol."},{"key":"15778_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154005","volume":"101","author":"N Perakakis","year":"2019","unstructured":"Perakakis, N. et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 101, 154005. https:\/\/doi.org\/10.1016\/j.metabol.2019.154005 (2019).","journal-title":"Metabolism"},{"issue":"1","key":"15778_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep.24624","volume":"55","author":"RP Myers","year":"2012","unstructured":"Myers, R. P. et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 55(1), 199\u2013208. https:\/\/doi.org\/10.1002\/hep.24624 (2012).","journal-title":"Hepatology"},{"issue":"6","key":"15778_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes, P. J. et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156(6), 1717\u20131730. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.042 (2019).","journal-title":"Gastroenterology"},{"issue":"5","key":"15778_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66(5), 1022\u20131030. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022 (2017).","journal-title":"J. Hepatol."},{"key":"15778_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2016.08.001","volume":"66","author":"SA Polyzos","year":"2017","unstructured":"Polyzos, S. A., Bugianesi, E., Kountouras, J. & Mantzoros, C. S. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-gamma agonists. Metabolism 66, 64\u201368. https:\/\/doi.org\/10.1016\/j.metabol.2016.08.001 (2017).","journal-title":"Metabolism"},{"issue":"8","key":"15778_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.metabol.2016.01.001","volume":"65","author":"JM Hazlehurst","year":"2016","unstructured":"Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F. & Tomlinson, J. W. Non-alcoholic fatty liver disease and diabetes. Metabolism 65(8), 1096\u20131108. https:\/\/doi.org\/10.1016\/j.metabol.2016.01.001 (2016).","journal-title":"Metabolism"},{"issue":"12","key":"15778_CR18","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2337\/dc16-2523","volume":"40","author":"JQ Purnell","year":"2017","unstructured":"Purnell, J. Q. et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: Results from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) study. Diabet. Care 40(12), 1756\u20131762. https:\/\/doi.org\/10.2337\/dc16-2523 (2017).","journal-title":"Diabet. Care"},{"issue":"2","key":"15778_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2013.07.052","volume":"230","author":"ET Oni","year":"2013","unstructured":"Oni, E. T. et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 230(2), 258\u2013267. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.052 (2013).","journal-title":"Atherosclerosis"},{"issue":"5","key":"15778_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo, T. et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 36(5), 947\u2013968. https:\/\/doi.org\/10.1016\/j.cmet.2024.04.006 (2024).","journal-title":"Cell Metab."},{"key":"15778_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.08.001","author":"K Lyu","year":"2020","unstructured":"Lyu, K. et al. A membrane-bound diacylglycerol species induces PKC\u03f5-mediated hepatic insulin resistance. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2020.08.001 (2020).","journal-title":"Cell Metab."},{"key":"15778_CR22","doi-asserted-by":"publisher","first-page":"1031633","DOI":"10.3389\/fendo.2022.1031633","volume":"13","author":"P Memaj","year":"2022","unstructured":"Memaj, P. & Jornayvaz, F. R. Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology. Front. Endocrinol. (Lausanne) 13, 1031633. https:\/\/doi.org\/10.3389\/fendo.2022.1031633 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"15778_CR23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","volume":"64","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64(5), 1167\u20131175. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.002 (2016).","journal-title":"J. Hepatol."},{"issue":"11","key":"15778_CR24","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.bbalip.2016.08.016","volume":"1861","author":"MK Montgomery","year":"2016","unstructured":"Montgomery, M. K. et al. Regulation of glucose homeostasis and insulin action by ceramide acyl-chain length: A beneficial role for very long-chain sphingolipid species. Biochim. Biophys. Acta 1861(11), 1828\u20131839. https:\/\/doi.org\/10.1016\/j.bbalip.2016.08.016 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"15778_CR25","first-page":"2570","volume":"61","author":"Neeland","year":"2018","unstructured":"Neeland, et al. Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes. Dallas. Heart Stud. Diabetol. 61, 2570\u20132579 (2018).","journal-title":"Dallas. Heart Stud. Diabetol."},{"key":"15778_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"15778_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20132428 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"15778_CR28","doi-asserted-by":"publisher","first-page":"305","DOI":"10.7326\/M15-1774","volume":"165","author":"K Cusi","year":"2016","unstructured":"Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Ann. Intern. Med. 165(5), 305\u2013315. https:\/\/doi.org\/10.7326\/M15-1774 (2016).","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"15778_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000 (2024).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15778-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:24:09Z","timestamp":1757449449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15778-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15778"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15778-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.A.S is a consultant and shareholder with Centaurus Therapeutics. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31031"}}